Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 9 |
| List of Tables | 9 | 1 |
| List of Figures | 10 | 1 |
| Introduction | 11 | 1 |
| Global Markets Direct Report Coverage | 11 | 1 |
| Chronic Kidney Disease (Chronic Renal Failure) Overview | 12 | 1 |
| Therapeutics Development | 13 | 2 |
| Pipeline Products for Chronic Kidney Disease (Chronic Renal Failure) Overview | 13 | 1 |
| Pipeline Products for Chronic Kidney Disease (Chronic Renal Failure) Comparative Analysis | 14 | 1 |
| Chronic Kidney Disease (Chronic Renal Failure) Therapeutics under Development by Companies | 15 | 3 |
| Chronic Kidney Disease (Chronic Renal Failure) Therapeutics under Investigation by Universities/Institutes | 18 | 1 |
| Chronic Kidney Disease (Chronic Renal Failure) Pipeline Products Glance | 19 | 3 |
| Late Stage Products | 19 | 1 |
| Clinical Stage Products | 20 | 1 |
| Early Stage Products | 21 | 1 |
| Chronic Kidney Disease (Chronic Renal Failure) Products under Development by Companies | 22 | 3 |
| Chronic Kidney Disease (Chronic Renal Failure) Products under Investigation by Universities/Institutes | 25 | 1 |
| Chronic Kidney Disease (Chronic Renal Failure) Companies Involved in Therapeutics Development | 26 | 36 |
| Acceleron Pharma, Inc. | 26 | 1 |
| Angion Biomedica Corp. | 27 | 1 |
| Astellas Pharma Inc. | 28 | 1 |
| AstraZeneca Plc | 29 | 1 |
| Bayer AG | 30 | 1 |
| Bio-inRen | 31 | 1 |
| BioAegis Therapeutics, Inc. | 32 | 1 |
| Boehringer Ingelheim GmbH | 33 | 1 |
| Bristol-Myers Squibb Company | 34 | 1 |
| Cellmid Limited | 35 | 1 |
| Complexa, Inc. | 36 | 1 |
| CTI BioPharma Corp. | 37 | 1 |
| Evotec AG | 38 | 1 |
| F. Hoffmann-La Roche Ltd. | 39 | 1 |
| Gilead Sciences, Inc. | 40 | 1 |
| GNI Group Ltd. | 41 | 1 |
| Intercept Pharmaceuticals, Inc. | 42 | 1 |
| Lupin Limited | 43 | 1 |
| Navya Biologicals Pvt Ltd | 44 | 1 |
| Nippon Zoki Pharmaceutical Co., Ltd. | 45 | 1 |
| Novartis AG | 46 | 1 |
| Otsuka Holdings Co., Ltd. | 47 | 1 |
| Prismic Pharmaceuticals, Inc. | 48 | 1 |
| Prolong Pharmaceuticals, LLC | 49 | 1 |
| ProMetic Life Sciences Inc. | 50 | 1 |
| Reata Pharmaceuticals, Inc. | 51 | 1 |
| Red Glead Discovery AB | 52 | 1 |
| RegenMedTX, LLC | 53 | 1 |
| Resverlogix Corp. | 54 | 1 |
| Sphaera Pharma Pvt. Ltd. | 55 | 1 |
| Stelic Institute &Co., Inc. | 56 | 1 |
| Taisho Pharmaceutical Co., Ltd. | 57 | 1 |
| Thrasos Therapeutics Inc. | 58 | 1 |
| Toray Industries, Inc. | 59 | 1 |
| VBS Pharmaceuticals | 60 | 1 |
| Vicore Pharma AB | 61 | 1 |
| Chronic Kidney Disease (Chronic Renal Failure) Therapeutics Assessment | 62 | 14 |
| Assessment by Monotherapy Products | 62 | 1 |
| Assessment by Combination Products | 63 | 1 |
| Assessment by Target | 64 | 4 |
| Assessment by Mechanism of Action | 68 | 4 |
| Assessment by Route of Administration | 72 | 2 |
| Assessment by Molecule Type | 74 | 2 |
| Drug Profiles | 76 | 106 |
| (palmidrol + silibinin) Drug Profile | 76 | 1 |
| ambrisentan Drug Profile | 77 | 2 |
| ANG-3070 Drug Profile | 79 | 1 |
| ANG-3281 Drug Profile | 80 | 1 |
| ANG-3586 Drug Profile | 81 | 1 |
| apabetalone Drug Profile | 82 | 9 |
| AS-2444697 Drug Profile | 91 | 1 |
| bardoxolone methyl Drug Profile | 92 | 5 |
| BI-655088 Drug Profile | 97 | 1 |
| BLR-400 Drug Profile | 98 | 1 |
| BMS-986177 Drug Profile | 99 | 1 |
| BRN-1889 Drug Profile | 100 | 1 |
| C-21 Drug Profile | 101 | 2 |
| CAB-101 Drug Profile | 103 | 1 |
| calcium succinate Drug Profile | 104 | 1 |
| CAR Peptide Drug Profile | 105 | 1 |
| cardiotoxin Drug Profile | 106 | 1 |
| Cell Therapy for Chronic Kidney Disease and Metabolic Disorders Drug Profile | 107 | 1 |
| CXA-10 Drug Profile | 108 | 2 |
| dapagliflozin propanediol Drug Profile | 110 | 7 |
| Drug for Kidney Diseases Drug Profile | 117 | 1 |
| F-351 Drug Profile | 118 | 2 |
| finerenone Drug Profile | 120 | 2 |
| INT-767 Drug Profile | 122 | 1 |
| KBP-5074 Drug Profile | 123 | 1 |
| LHW-090 Drug Profile | 124 | 1 |
| NAV-003 Drug Profile | 125 | 1 |
| NZ-419 Drug Profile | 126 | 1 |
| obinutuzumab Drug Profile | 127 | 7 |
| pacritinib Drug Profile | 134 | 11 |
| PBI-4050 Drug Profile | 145 | 5 |
| PBI-4419 Drug Profile | 150 | 1 |
| Recombinant Plasma Gelsolin Replacement for Renal Disease Drug Profile | 151 | 1 |
| Recombinant Protein to Agonize ALK and BMP Receptors for Alport Syndrome, Kidney Diseases, Metabolic Disorders and Osteoarthritis Drug Profile | 152 | 2 |
| Sanguinate Drug Profile | 154 | 2 |
| Small Molecule to Agonize CaSR for Chronic Kidney Disease and Primary Hyperparathyroidism Drug Profile | 156 | 1 |
| Small Molecule to Inhibit Sodium-Phosphate Cotransporter 2b for Chronic Kidney Disease and Hypertension Drug Profile | 157 | 1 |
| Small Molecule to Inhibit Soluble Epoxide Hydrolase for Chronic Kidney Disease Drug Profile | 158 | 1 |
| Small Molecules for Chronic Kidney Disease Drug Profile | 159 | 1 |
| Small Molecules for Chronic Kidney Disease Drug Profile | 160 | 1 |
| Small Molecules to Inhibit SphK2 for Autoimmune Disorders, Chronic Kidney Disease, Fibrosis, Neurodegenerative Diseases and Oncology Drug Profile | 161 | 1 |
| sotatercept Drug Profile | 162 | 5 |
| SP-20103 Drug Profile | 167 | 1 |
| SPR-494 Drug Profile | 168 | 1 |
| STNM-310 Drug Profile | 169 | 1 |
| Synthetic Peptide to Modulate GHSR for Chronic Kidney Disease Drug Profile | 170 | 1 |
| Synthetic Peptides for Chronic Kidney Disease Drug Profile | 171 | 1 |
| TNT-009 Drug Profile | 172 | 2 |
| tolvaptan Drug Profile | 174 | 4 |
| torsemide ER Drug Profile | 178 | 1 |
| TRC-101 Drug Profile | 179 | 1 |
| TS-143 Drug Profile | 180 | 1 |
| Vida-5 Drug Profile | 181 | 1 |
| Chronic Kidney Disease (Chronic Renal Failure) Dormant Projects | 182 | 3 |
| Chronic Kidney Disease (Chronic Renal Failure) Discontinued Products | 185 | 1 |
| Chronic Kidney Disease (Chronic Renal Failure) Product Development Milestones | 186 | 10 |
| Featured News &Press Releases | 186 | 1 |
| Sep 12, 2016: AstraZeneca announces two new phase IIIb trials for Forxiga in chronic kidney disease and chronic heart failure | 186 | 1 |
| Aug 05, 2016: CDSCO requests further data for granting additional indication for Ambrisentan tablet 5mg/10mg | 186 | 1 |
| Aug 04, 2016: The Life Sciences Report Examines Resverlogix New Trial | 187 | 1 |
| Jul 21, 2016: Resverlogix Announces Dosing of First Two Patients in Expanded Renal and Orphan Programs | 187 | 1 |
| May 24, 2016: Resverlogix Presents New Complement Data and Establishes Renal Clinical Advisory Board at the 53rd Annual European Renal Association - European Dialysis &Transplant Association Congress (ERA-EDTA) | 188 | 1 |
| Nov 09, 2015: Resverlogix Presents Important New Data at the Annual American Society of Nephrology Kidney Week Conference | 189 | 1 |
| Aug 04, 2015: International Clinical Steering Committee Announced for Resverlogix's Phase 3 BETonMACE Clinical Trial with RVX-208 "apabetalone" | 189 | 2 |
| Jun 02, 2015: Combination of Agents in NEFROSIL found to be Highly Effective in Renal Disease Model | 191 | 1 |
| Jun 01, 2015: Resverlogix Presents New Data at 52nd Annual European Renal Association - European Dialysis &Transplant Association Congress | 191 | 1 |
| Apr 07, 2015: Resverlogix Receives Two Patents For RVX-208 In China | 192 | 1 |
| Nov 13, 2014: Sotatercept Data from the Phase 2a Clinical Trial in Hemodialysis Patients Presented at the American Society of Nephrology Kidney Week 2014 | 192 | 1 |
| Oct 22, 2014: Acceleron Announces Educational Webcast on Chronic Kidney Disease - Mineral and Bone Disorder | 193 | 1 |
| Jul 02, 2014: Future Development Direction for Bardoxolone Methyl (RTA 402) | 193 | 1 |
| Apr 23, 2014: Acceleron and Celgene Announce Interim Clinical Data for Sotatercept Demonstrating Dose Dependent Increases in Hemoglobin in Patients with End Stage Renal Disease on Hemodialysis | 194 | 1 |
| Mar 17, 2014: Acceleron and Celgene Announce Interim Clinical Data for Sotatercept in Patients with End Stage Renal Disease on Hemodialysis at the 2014 National Kidney Foundation Spring Clinical Meeting | 194 | 2 |
| Appendix | 196 | 2 |
| Methodology | 196 | 1 |
| Coverage | 196 | 1 |
| Secondary Research | 196 | 1 |
| Primary Research | 196 | 1 |
| Expert Panel Validation | 196 | 1 |
| Contact Us | 196 | 1 |
| Disclaimer | 197 | 1 |